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Comments to the Editor on “Outcomes and Costs of 
Risperidone versus Olanzapine in Patients with Chronic 
Schizophrenia or Schizoaffective Disorders: A Markov Model”
To the Editor—We read with interest Vera-Llonch
et al.’s modeling of their expected outcomes of
schizophrenia treatment with risperidone or olanza-
pine. It seems to us that models are of greatest value
when they lead us to new, unintuitive predictions
about the relationships between variables. They
may be especially useful when available data are not
yet sufﬁcient to answer questions of interest. Simi-
larly, when actual data conﬂict with estimates from
a theoretical model, the value of the model is sus-
pect. Vera-Llonch and colleagues are modeling
questions of compliance and cost that can be and
have been measured directly. They fail to emphasize
adequately that their conclusions are potentially
misleading. The abstract highlights a striking con-
clusion that patients are more than twice as likely to
discontinue olanzapine versus risperidone treat-
ment. This is starkly contradicted by available data.
When evaluating medication compliance and its
associated economic effects, we would direct the
reader to go beyond hypothetical models and eval-
uate the actual ﬁndings. The authors acknowledge
that randomized trials have not demonstrated the
advantage in discontinuation rate that their model
expects for risperidone. Furthermore, in naturalistic
studies to this point, olanzapine use has been asso-
ciated with greater adherence to medication ther-
apy, and persistence on medication for longer
periods of time relative to risperidone [1–7]. Addi-
tionally, at least four well-designed observational
studies have shown that the total cost of treatment
is actually equal or lower for olanzapine-treated
patients versus risperidone recipients [2,5,8,9].
As results of the Vera-Llonch et al. model conﬂict
with actual experience, the accuracy and adequacy
of the model’s assumptions are called into question.
For example, although they assume that risperidone
treatment is less likely to be associated with treat-
ment-emergent diabetes than olanzapine treatment,
we do not believe that available evidence [10]
allows that conclusion. Furthermore, a large con-
tributor to the model’s results is its assumptions
about proportions of signiﬁcant weight gain
between groups. The model assumes an incidence of
only 3.7% for treatment-emergent weight gain
(deﬁned as an increase in body weight of at least
7%) with risperidone, which seems far below the
18% mentioned in the risperidone label for 6–
8 weeks of treatment. Finally, discontinuation rates
due to hyperprolactinemia and extrapyramidal
symptoms were based on actual research data [11],
6% and 14%, respectively, whereas discontinuation
rates due to diabetes and weight gain were arbitrar-
ily set at a high level, 45% and 100%, respectively.
It is likely that these or other dubious assumptions
underlie conclusions that are contradicted by
empiric ﬁndings.
The authors acknowledge that their model may
be inconsistent with current clinical practice. Their
manuscript would be more objective if it more
clearly reﬂected throughout the potential fallacy of
assumptions and conclusions.—Jerry D. Clewell,
PharmD, MBA BCPS and Robert W. Baker, MD, Eli
Lilly and Company, Indianapolis, IN, USA.
References
1 Opolka JL, Rascati KL, Brown CM, Gibson PJ.
Role of ethnicity in predicting antipsychotic med-
ication adherence. Ann Pharmacother 2003;37:
625–30.
2 Rascati K, Johnsrud MT, Crismon LM, et al. Olan-
zapine versus risperidone in the treatment of schiz-
ophrenia: a comparison of costs among Texas
Medicaid patients. Pharmacoeconomics 2003;21:
683–97.
3 Zhao Z, Damler RM, Jackson EA, Ramsey JL.
Atypical antipsychotic treatment adherence and
persistence in a state Medicaid program. Paper pre-
sented at: Institute for Psychiatric Services Annual
Meeting, October 2003, Boston, MA.
4 Zhao Z, Tunis SL, Lage MJ. Medication treatment
patterns following initiation on Olanzapine versus
risperidone: a retrospective analysis. Clin Drug
Invest 2002;22:741–9.
5 Gibson P, Damler R, Jackson E, et al. The impact
of olanzapine, risperidone, or haloperidol on the
cost of schizophrenia care in a Medicaid popula-
tion. Value Health 2004;7:22–35.
6 Zhu B, Ascher-Svanum H, Faries D, et al. Differ-
ences among antipsychotics in the time to all-cause
drug discontinuation: results from a longitudinal
To the Editor176
naturalistic study of schizophrenia. Paper presented
at: American Psychiatric Association Annual Meet-
ing, May 17–22, 2003, San Francisco, CA.
7 Haro JM, Novick D, Belger M, et al. Continuation
of antipsychotic treatment in the outpatient set-
ting: 12-month results from the schizophrenia out-
patient health outcomes (SOHO) study. Presented
at the 157th Annual Meeting of the American Psy-
chiatric Association (APA), May 1–6, 2004, New
York, NY.
8 Sclar D, Robison LM, Skaer TL, et al. Cost and use
patterns for atypical antipsychotics among Medic-
aid patients. Poster (NR226) presented at: Ameri-
can Psychiatric Association Annual Meeting, 2003,
San Francisco, CA.
9 Zhao Z. Economic outcomes associated with olan-
zapine versus risperidone in the treatment of
uncontrolled schizophrenia. Curr Med Res Opin
2004;20:1039–48.
10 Citrome LL, Jaffe AB. Relationships of atypical
antipsychotics with development of diabetes melli-
tus. Ann Pharmacother 2003;37:1849–57.
11 Conley RR, Mahmoud R. A randomized double-
blind study of risperidone and olanzapine in the
treatment of schizophrenia or schizoaffective dis-
order. Am J Psychiatry 2001;158:765–74.
